Insilico Medicine (03696) Nominates Peripheral-Restricted VAV1 Molecular Glue Degrader with Potential for Treating Multiple Autoimmune Diseases

Zhito Finance APP News, Insilico Medicine (03696) announced that the Company has nominated ISM9546 as a preclinical candidate compound (PCC). It is an innovative, orally available, peripherally restricted VAV1 molecular glue degrader, with potential for the treatment of multiple autoimmune diseases, including inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). Empowered by Insilico Medicine's proprietary Pharma.AI solution, ISM9546 is not only the Company's 35th PCC nominated since 2021, but also achieves a balance between efficacy and safety, demonstrating nanomolar-level activity in multiple cellular assays and, through its peripherally restricted characteristics, potentially reducing risks associated with the central nervous system (CNS).